M1FG
AUPH icon

Mach-1 Financial Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Mach-1 Financial Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,348
Closed -$181K – 174
2025
Q4 		$181K Buy
+11,348
New +$161K 0.04% 288

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mach-1 Financial Group's AUPH Position: Q1 2026 in Review

Mach-1 Financial Group sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 11,348 shares — an estimated $181K sold.

Mach-1 Financial Group first reported a position in AUPH in Q4 2025 and held it in 1 quarter. The position peaked at $181K in Q4 2025. 260 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Mach-1 Financial Group reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mach-1 Financial Group sold 11,348 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $181K.
  • Mach-1 Financial Group first reported a position in Aurinia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Aurinia Pharmaceuticals position peaked at $181K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Mach-1 Financial Group's 13F filing for Q1 2026, filed 13 May 2026.